Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin and BEAM with Rituximab Maintenance in DLBCL Transplant
NCT00591630Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2007
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2007; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00591630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591630.